Does lymphovascular invasion trump POLE mutation in early-stage uterine cancer adjuvant therapy decisions?

In the current ESGO guidelines, stage I and II POLE types are always low risk, irrespective of substantial LVSI, with a predicted risk of recurrence being less than 10 percent, and favoring observation. That being said, in practice, I do offer brachytherapy, as I feel it is a low morbidity procedure...

Would favor brachy alone, although observation is reasonable, as it’s a low-risk disease and the absolute benefit of any intervention is small.